道德规范和公司合规
PARCE QUE CE QU'ON FAIT COMPTE.
Pour les entreprises du Groupe Olympus dans le monde entier, notre objectif est de rendre la vie des gens plus saine, plus sûre et plus enrichissante, et cette responsabilité est toujours à l'avant-garde de nos esprits. Bien que nous nous efforcions de toujours obtenir de forts résultats d'affaires, la façon dont nous obtenons ces résultats est tout aussi importante.
De bons résultats d'affaires ne sont pas durables sans un engagement à faire la bonne chose de la bonne façon.
Être fidèle à nos clients, notre environnement, et notre entreprise, et se respecter les uns les autres sont des attentes fondamentales de chaque employé et partenaire d'affaires Olympus.
Chez Olympus, nous avons une philosophie d'entreprise, qui se compose de notre objectif, de nos valeurs fondamentales et des comportements associés. Le Code de conduite des affaires d'Olympus Corporation of the Americas s'aligne sur le Code de conduite mondial d'Olympus et sert de guide pour la conduite responsable des affaires.
L'engagement d'Olympus envers une culture de conformité est pleinement soutenu par la haute direction. Olympus favorise cette culture de conformité en élaborant des politiques claires et cohérentes, en organisant des formations régulières en matière de conformité, en encourageant une communication ouverte, en répondant en temps opportun aux préoccupations et en cernant les risques et en administrant des mesures correctives lorsque nécessaire.
 | Le programme de conformité Olympus a été élaboré sur la base des directives publiées par le gouvernement fédéral des États-Unis, et ses éléments fondamentaux sont également compatibles avec le Code d'éthique des interactions de l'Advanced Medical Technology Association (AdvaMed) avec les professionnels de la santé. Aux États-Unis, Olympus joue un rôle actif dans AdvaMed et a certifié le Code AdvaMed . |
OPEN PAYMENTS REPORTING
Open Payments is a U.S. national disclosure program created by the Affordable Care Act that increases public awareness of financial relationships between the health care industry (like medical device manufacturers and pharmaceutical companies) and physicians or teaching hospitals. Olympus is required to report payments or transfers of value they make to physicians or teaching hospitals. The Centers for Medicare & Medicaid Services (CMS) collects this data annually and makes it publicly available and searchable online.
Visit https://openpaymentsdata.cms.gov to use the CMS Open Payments Data search tool to search for information regarding payments made by Olympus to doctors or teaching hospitals. You can download all Open Payments data in detail, or search based on the Physician or Teaching Hospital receiving the payment, or the Company making the payment. Additional information on Open Payments is available on the Centers for Medicare and Medicaid Services website at https://www.cms.gov/OpenPayments.
Any questions/inquiries regarding the Olympus Open Payments report can be directed to AggSpend@olympus.com
REPORTABLE PAYMENTS AND TRANSFERS OF VALUE
Olympus collaborates and interacts with health care providers in order to advance new, safe and effective medical technologies that lead to improvements in patient care, helping people around the world lead safer, healthier and more fulfilling lives.
Olympus values its relationship with health care providers and is committed to the transparency afforded by the Open Payments Reporting. Olympus’ Open Payments report includes the following types of transfers of value it makes to Physicians and Teaching Hospitals:
- Compensation paid to health care professionals for services performed for the Company
- Educational items (e.g., medical text books, scientific journal articles)
- Food, beverage, travel, and lodging relating to consulting services, product training, and other business related activities
- Education on the use of our products and related treatments
- Research on new products to help advance patient care
- Charitable contributions
- Royalties or license payments
- Grants to support independent healthcare education
- Space rental or facility fees associated with product training, clinical studies, or booth/exhibit space
CALIFORNIA COMPLIANCE LAW
Olympus is committed to conducting business ethically and in compliance with all applicable laws, regulations, guidelines, and policies.
Statement regarding compliance with California Health & Safety Code § 119402
Olympus has established and is operating in accordance with a Comprehensive Compliance Program (“CCP”). Because Olympus is a medical device manufacturer and not a pharmaceutical manufacturer, certain guidance set forth in the PhRMA Code on Interactions with Health Care Professionals and the Office of Inspector General (OIG) Compliance Guidance for Pharmaceutical Manufacturers does not apply to Olympus and its operations. Consistent with this, Olympus is making good faith efforts to conform its CCP to applicable requirements of Sections 119400-119402 of the California Health & Safety Code and will generally follow the Code of Ethics adopted by the Advanced Medical Technology Association (AdvaMed).
To obtain a print version of this document, please contact Olympus’ Integrity Hotline at 1-844-277-1698 or email compliance@olympus.com.
GOVERNMENT SETTLEMENT AGREEMENTS AS OF MARCH, 2019
Dear Olympus Employees & Families, Customers, Partners and Community Stakeholders,
On February 29, 2016, Olympus Corporation of the Americas (OCA) entered into two, three-year Deferred Prosecution Agreements (DPAs) to resolve two criminal complaints for federal Anti-kickback statute violations and Foreign Corrupt Practices Act violations. Pursuant to the Agreements, Olympus agreed to engage an outside monitor. Larry A. Mackey, a partner with Barnes & Thornburg LLP, was selected as the Monitor. Mr. Mackey and his team have worked collaboratively with OCA for the three years.
The DPAs have concluded successfully and the criminal Complaints against OCA have been dismissed.
Over the past three years, the Monitor team has been engaged in a number of ways in reviewing and enhancing OCA’s compliance program, including: monitoring business activities, assessing the effectiveness of OCA’s compliance program, evaluating controls toward compliance risk reduction, and making constructive recommendations for improvement. The Monitor has observed that Olympus has invested significant resources to build a robust program that ensures adherence with all applicable laws and regulations. These have included the development of appropriate internal policies aligned with industry best practices, robust training requirements for Olympus employees, and the continual monitoring of company activities.
Mr. Mackey’s final reports to the government were extremely positive, noting that not only had OCA met and even exceeded its obligations under the DPAs, but that it also demonstrated across the organization, from senior executive leadership through its sales force, a culture of integrity and compliance. He stated that, as a result, the problematic conduct that led to the DPAs is very unlikely to recur, that the company has proven that its systems, policies and procedures are sustainable and that there is no further need for oversight. Mr. Mackey commended OCA for committing to and implementing compliance “best practices” in the United States and Latin America.
In 2016, OCA also entered into a civil settlement pursuant to which it paid $306 million and entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) at the United States Department of Health and Human Services. Under this agreement, OCA agreed to undertake certain obligations to promote compliance with Federal health care program and FDA requirements. OCA also agreed to notify health care providers about the settlement and inform them that they can report any questionable practices by OCA representatives using the information set out further below. The five-year CIA is scheduled to conclude on February 28, 2021.
Questions Regarding the Corporate Integrity Agreement Referenced Above
Please call OCA at 1-866-861-8386 or send your inquiries via email to Compliance@olympus.com if you have questions about the settlements.
To Report Inappropriate Product Promotion or Questionable Conduct
Please call the Olympus Integrity Line at:
U.S., Canada & Puerto Rico: 1-844-277-1698
Canadian French: 1-855-350-9393
Brazil: 0800-892-0649
Mexico: 001-855-232-1301
Alternatively, visit http://olympus.ethicspoint.com to report any instances in which you believe that an OCA sales representative inappropriately promoted a product or engaged in other questionable conduct.
The mission of Olympus is to make people’s lives healthier, safer, and more fulfilling. We remain committed to achieving this mission, both as individuals and as a company, with uncompromised integrity.
Anti-Kickback Statute - OCA Corporate Integrity Agreement
INTEGRITY LINE
| Olympus strives for ethical and compliant behavior. Every Olympus Representative (including Company personnel and agents) has a duty to report any actual or suspected violations of any laws, regulations, government health care program requirements, internal policies and procedures, or inappropriate actions. To ensure that allegations of improper or illegal conduct, activities or practices are heard and addressed, OCA maintains an anonymous, confidential reporting system (the "Integrity Line"). |  |
The Integrity Line is maintained by a third-party, Ethics Point. Employees, customers, business partners and other third parties may make reports to the Integrity Line 24 hours a day, 7 days a week, every day of the year, by telephone or by using the internet. Ethics Point provides issue reporters with multi-lingual support and translation services.
When using the Integrity Line, issue reporters may elect to remain anonymous. In all cases, reports are treated with the utmost discretion. To maintain anonymity, issue reporters are assigned a unique code, called a “report key” within the Ethics Point system after reports are submitted, which is intended for the reporter’s eyes only.
The Integrity Line is accessed in the following manner:
Telephone:
U.S., Canada & Puerto Rico: 1-844-277-1698
Canada-French: 1-855-350-9393
Costa Rica: 0800-011-1248
Mexico: 001-855-232-1301
Brazil: 0800-892-0649
Encrypted website: http://olympus.ethicspoint.com
In addition to the Integrity Line, OCA welcomes any reporting of concerns about unethical or unlawful conduct directly to management, Human Resources, the OCA Legal Department and/or the OCA Compliance Department. The OCA Compliance Department can be reached directly via phone at 484-896-4472 or via email at compliance@olympus.com. Company policy prohibits retaliation against any individual for reporting concerns to the Integrity Line or directly to management in good faith.